IPM Take
Antimicrobial stewardship has a political weakness when it is reduced to telling people to use fewer antibiotics. In some communities, unnecessary treatment is a major problem. In others, the crisis is that a patient cannot reach a clinician, obtain a diagnosis or access an effective antibiotic at all.
WHO’s new guidance forces those realities into the same conversation. An AMR strategy that protects antibiotics by making appropriate treatment harder to reach is not successful stewardship. It is simply inequity wearing a public-health label.
Executive Summary
WHO has published new guidance on integrating equity into national action plans on antimicrobial resistance, arguing that inequities remain insufficiently addressed in AMR policy and implementation.
The guidance provides 20 recommendations across 13 core interventions within WHO’s people-centred AMR approach. It examines equity through three practical areas: water, sanitation and hygiene; access to health services and essential antibiotics; and surveillance of antimicrobial resistance and antimicrobial use.
Countries are encouraged to adapt the recommendations to their own circumstances and progressively build equity into national AMR action.
Why it matters
- Policymakers: AMR targets need to measure who gains and who loses from an intervention, not only whether overall antibiotic consumption moves.
- Health systems: Stewardship must distinguish inappropriate antibiotic use from populations that remain unable to obtain essential antibiotics when genuinely needed.
- Communities: Poor sanitation, weak access to diagnostics and barriers to healthcare can increase both exposure to resistant infection and the consequences when treatment fails.
Antimicrobial resistance policy often starts with a familiar instruction: antibiotics must be used more carefully. That is true, but it is not universally sufficient, and in some settings it can badly describe the problem facing patients.
A person who can obtain antibiotics without adequate diagnosis may be exposed to unnecessary treatment and contribute to selective pressure. Another person, living perhaps only a few kilometres away, may have a serious bacterial infection and be unable to obtain any effective antibiotic at all. Both are part of the AMR crisis. A policy that focuses exclusively on reducing consumption risks seeing only the first.
WHO’s new equity guidance is important because it asks governments to examine those contradictions directly. The organisation identifies three areas where inequality can shape antimicrobial resistance: water and sanitation, access to healthcare and essential antibiotics, and the systems used to monitor resistance and antimicrobial use. Together they broaden AMR from a prescribing problem into a question of how health systems distribute risk and protection.
Water and sanitation are the clearest example. Communities without reliable clean water or adequate sanitation face more infectious exposure, which increases illness and the need for antimicrobial treatment. If policy then concentrates downstream on stewardship without addressing the conditions generating infection upstream, the health system asks disadvantaged populations to carry a burden that infrastructure should have prevented.
Access to antibiotics creates the opposite tension. Global discussions frequently and correctly warn about antimicrobial overuse, but lack of access remains lethal. The objective is not fewer antibiotics under all circumstances. It is the right antibiotic, for the right patient, at the right time, supported where possible by diagnosis and clinical oversight. Countries need policy sophisticated enough to restrict unnecessary use without turning stewardship into another barrier for poor, rural or marginalised patients.
Surveillance contains its own inequality. Resistance maps are only as representative as the laboratories and facilities feeding data into them. If specimens mainly come from major urban hospitals, national AMR intelligence may systematically under-represent communities with weaker access to diagnostics. The places carrying some of the greatest infectious-disease vulnerability can then become the least visible in the datasets used to allocate resources.
WHO’s twenty recommendations are designed to make governments ask these questions within their existing national action plans rather than bolt equity onto AMR as a separate social policy. That approach matters because inequity is not simply an ethical concern surrounding resistance. It can alter the effectiveness of the intervention itself.
A stewardship campaign that patients cannot understand will not work as intended. A surveillance programme without rural laboratory access will produce an incomplete picture. A restriction policy without reliable diagnostics may leave clinicians choosing empirically with fewer tools. A national plan that assumes everyone can reach a healthcare facility begins from a fiction.
There is also a political advantage to making the distributional consequences explicit. AMR policy will require difficult decisions about medicine access, diagnostic investment, hospital infection control, agriculture, sanitation and health-system financing. Governments need to know not only whether those measures reduce resistance in aggregate, but whether they shift costs onto people who already have the least capacity to absorb them.
The age of generic AMR action plans should be ending. Countries increasingly know what the broad interventions are. The tougher task is making them work for different populations living inside very different health realities.
Resistance is biological. The conditions that allow it to spread and kill are deeply social.
Policy has to address both.
